University of South Australia scientists have developed a powerful new way to uncover the genetic interactions that fuel cancer progression, paving the way for earlier and more precise treatments.

The compound, called I3IN-002, disrupts the ability of a protein known as IGF2BP3 to bind and stabilize cancer-promoting RNAs, a mechanism that fuels aggressive forms of acute leukemia.

Reducing calorie intake helps cancer-fighting immune cells do their jobs more effectively, reports a study by Van Andel Institute scientists and collaborators. The findings lay the groundwork for developing dietary strategies to boost the effects of a powerful class of cancer immunotherapies.

This cohort study of older traditional Medicare beneficiaries who were diagnosed with common metastatic cancers found a mean of 40 to 62 health care contact days in the year after diagnosis. Health care contact days increased from 2008 to 2019, suggesting that treatment advancements and/or care inefficiencies may have imposed additional burdens on beneficiaries. The results of this study suggest that oncology teams should discuss expected contact days and related burdens when developing care goals and treatment plans with older adult patients.

Five LMU researchers have been awarded Consolidator Grants by the European Research Council. Their projects deal with climate change, strokes, quantum physics, mitochondria, and cancer diagnosis.

Patients with relapsed or refractory (R/R) multiple myeloma who received a combination of teclistamab, a bispecific monoclonal antibody, and daratumumab, a CD38-directed monoclonal antibody, were 83% more likely to be alive without disease progression compared with those who received standard second-line therapies at a median of nearly 35 months of follow-up, according to the results of a new trial.

In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease progression and was well tolerated with a more favorable safety profile when compared with bendamustine plus rituximab (BR) in patients with previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).